Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO)

Price 1.60p on 24-04-2024 at 16:30:02
Change -0.021p -1.29%
Buy 1.63p
Sell 1.586p
Buy / Sell HEMO Shares
Last Trade: Buy 61,819.00 at 1.616p
Day's Volume: 5,063,450
Last Close: 1.608p
Open: 1.698p
ISIN: GB00BYX3WZ24
Day's Range 1.60p - 1.70p
52wk Range: 1.125p - 6.30p
Market Capitalisation: £21m
VWAP: 1.629739p
Shares in Issue: 1,342m

Recent Trades History Hemogenyx (HEMO)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 61,819 1.616p Suspected BUY Trade
15:29:42 - 24-Apr-24
Buy* 475 1.626p Ordinary
15:29:24 - 24-Apr-24
Buy* 1,531 1.624p SI Trade
15:12:26 - 24-Apr-24
Buy* 3,067 1.622p Ordinary
15:02:18 - 24-Apr-24
Sell* 7,500 1.586p Ordinary
15:00:09 - 24-Apr-24
Sell* 100,000 1.586p Ordinary
14:49:58 - 24-Apr-24
Sell* 100,000 1.5826p Ordinary
14:49:18 - 24-Apr-24
Sell* 250,000 1.60p Automatic Execution
14:47:51 - 24-Apr-24
Sell* 200,000 1.60p Ordinary
14:47:44 - 24-Apr-24
Sell* 100,000 1.6104p Ordinary
14:45:40 - 24-Apr-24

Share Price History for Hemogenyx

Time period:
to
Date Open High Low Close Volume

Share News for Hemogenyx

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

29th Feb 2024 14:04

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing. Read More

Hemogenyx shares rise on potential for CBR to treat brain diseases

16th Feb 2024 11:27

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases. Read More

Hemogenyx says CBR can be used intranasally to treat viral infections

14th Feb 2024 10:14

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections. Read More

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

9th Feb 2024 10:00

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month. Read More

IN BRIEF: Hemogenyx hails US patent application progress

2nd Feb 2024 10:44

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies. Read More

FTSE 100 Latest
Value8,040.38
Change-4.43

Login to your account

Forgot Password?

Not Registered